Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by RBF Capital LLC

RBF Capital LLC lessened its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 63.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 54,929 shares of the company's stock after selling 93,522 shares during the quarter. RBF Capital LLC owned about 0.07% of Atea Pharmaceuticals worth $183,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Atea Pharmaceuticals in the 3rd quarter valued at about $99,000. Intech Investment Management LLC grew its stake in shares of Atea Pharmaceuticals by 236.0% in the 4th quarter. Intech Investment Management LLC now owns 35,989 shares of the company's stock valued at $121,000 after purchasing an additional 25,278 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Atea Pharmaceuticals by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 45,391 shares of the company's stock valued at $152,000 after purchasing an additional 9,865 shares during the period. HighTower Advisors LLC purchased a new stake in shares of Atea Pharmaceuticals during the fourth quarter worth approximately $168,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Atea Pharmaceuticals by 5.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 73,883 shares of the company's stock worth $248,000 after purchasing an additional 3,882 shares during the period. Institutional investors and hedge funds own 86.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. William Blair restated an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday, March 7th. Morgan Stanley reduced their price objective on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th.

Atea Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ:AVIR traded up $0.07 on Monday, reaching $2.96. 220,703 shares of the company were exchanged, compared to its average volume of 293,282. The company has a 50-day moving average of $2.97 and a 200-day moving average of $3.16. The firm has a market cap of $253.15 million, a price-to-earnings ratio of -1.43 and a beta of 0.17. Atea Pharmaceuticals, Inc. has a 1-year low of $2.60 and a 1-year high of $4.15.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). As a group, analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.